^
    Back
    Association details:
    Biomarker:BRAF wild-type
    Cancer:Non Small Cell Lung Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    IASLC-WCLC 2023
    Title:

    ERBB3 and BRAF Mutations as Potential Biomarkers in Non-Small Cell Lung Cancer Patients Under Immunotherapy-Based Treatments

    Published date:
    08/08/2023
    Excerpt:
    Liquid biopsy samples from 63 stage IV NSCLC patients were collected before first-line treatment with immunotherapy or chemo-immunotherapy….the median PFS and OS for patients with BRAF wt tumors were 5.36 and 12.00 months, respectively (LogRank p-value of 0.021 for PFS...
    Secondary therapy:
    Chemotherapy